Drug Trial Radar · NCT04023396
Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis
Last checked: Nov 19, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
217
Actual
Start
Jan 13, 2020
Primary completion
Feb 23, 2023
Study completion Feb 23, 2023
Sponsor
- Lead sponsor
- Abivax S.A.Industry
- Sponsor type
- Industry
- First posted
- Jul 17, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase 2b study to evaluate the long-term efficacy and safety study of ABX464 50mg as maintenance therapy in patients with moderate to severe Ulcerative Colitis.
Conditions
- Ulcerative Colitis
Interventions
ABX464Drug
ABX464 All subjects will receive ABX464 administered at 50 mg o.d for an overall period of 96 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Patients With Clinical Remission at Week 48 Compared to Baseline of Induction Study (ABX464-103)Time frame: week 48
Locations
120 sites in 16 countries. Site status is shown where the registry gives one.
Medizinische Universität Innsbruck
Innsbruck, Austria
Klinikum Klagenfurt am Wörthersee
Klagenfurt, Austria
Ordensklinikum Linz GmbH - Barmherzige Schwestern
Linz, Austria
AKH - Medizinische Universität Wien
Vienna, Austria
Gomel Regional Clinical Hospital
Homyel, Belarus
Minsk city diagnostic center
Minsk, Belarus
Regional Clinical Hospital
Minsk, Belarus
Vitebsk Regional Clinical Hospital
Vitebsk, Belarus
Vitebsk regoinal clinical specialized center
Vitebsk, Belarus
AZ Sint-Lucas
Bruges, Belgium
C. H. U. St-Pierre
Brussels, Belgium
University Hospitals Leuven - campus Gasthuisberg
Leuven, Belgium
Brandon Medical Arts Clinic
Brandon, Canada
South Edmonton Gastroenterology
Edmonton, Canada
LHSC - Victoria Hospital
London, Canada
The Ottawa Hospital - General Campus
Ottawa, Canada
Mount Sinai Hospital
Toronto, Canada
Fakultni nemocnice u sv. Anny v Brne
Brno, Czechia
Hepato-Gastroenterologie HK s.r.o.
Hradec Králové, Czechia
MUDr. GREGAR s.r.o.
Olomouc, Czechia
Fakultni nemocnice Ostrava
Ostrava-Kunčice, Czechia
Nemocnice Na Bulovce
Prague, Czechia
Thomayerova nemocnice
Prague, Czechia
Nemocnice Slany
Slaný, Czechia
CHU Amiens - Hopital Sud
Amiens, France
CHU Besançon - Hôpital Jean Minjoz
Besançon, France
CHU Clermont Ferrand - Hôpital d'Estaing
Clermont-Ferrand, France
Hôpital Beaujon
Clichy, France
CHU de Grenoble - Hôpital Nord
Grenoble, France
Centre Hospitalier Départemental Les Oudairies
La Roche-sur-Yon, France
CHU Lille - Hôpital Claude Huriez
Lille, France
Hôpital Nord - CHU Marseille
Marseille, France
Hopital Saint Eloi
Montpellier, France
CHU Nantes - Hôtel Dieu
Nantes, France
CHU Nice - Hôpital de l'Archet 2
Nice, France
CHU Reims - Hôpital Robert Debré
Reims, France
CHU Rennes - Hôpital Pontchaillou
Rennes, France
CHU de Rouen - Hôpital Charles Nicolle
Rouen, France
CHU Saint Etienne - Hôpital Nord
Saint-Etienne, France
CHU Strasbourg - Hôpital Hautepierre
Strasbourg, France
Showing 40 of 120 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.